Comparison

Lixisenatide vs. Pramlintid

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Lixisenatide

Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Lixisenatide	Pramlintid
Germany	Prescription	Unapproved
JP	Prescription	—
United States	Unapproved	Prescription

Full entries

Frequently asked questions

What is the difference between Lixisenatide and Pramlintid?: Lixisenatide is classified as "Metabolic", while Pramlintid is classified as "Metabolic". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Lixisenatide or Pramlintid?: The highest available evidence level is "Human RCT" for Lixisenatide and "Human RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Lixisenatide and Pramlintid in Germany and the United States?: Germany: Lixisenatide — Prescription, Pramlintid — Unapproved. United States: Lixisenatide — Unapproved, Pramlintid — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Lixisenatide

Pramlintid

Germany

Prescription

Unapproved

Prescription

—

United States

Unapproved

Prescription

Frequently asked questions

What is the difference between Lixisenatide and Pramlintid?

Lixisenatide is classified as "Metabolic", while Pramlintid is classified as "Metabolic". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Lixisenatide or Pramlintid?

The highest available evidence level is "Human RCT" for Lixisenatide and "Human RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Lixisenatide and Pramlintid in Germany and the United States?

Germany: Lixisenatide — Prescription, Pramlintid — Unapproved. United States: Lixisenatide — Unapproved, Pramlintid — Prescription. These are factual summaries with source and review date on the individual pages.